CN107074850A - 新化合物 - Google Patents
新化合物 Download PDFInfo
- Publication number
- CN107074850A CN107074850A CN201580052202.3A CN201580052202A CN107074850A CN 107074850 A CN107074850 A CN 107074850A CN 201580052202 A CN201580052202 A CN 201580052202A CN 107074850 A CN107074850 A CN 107074850A
- Authority
- CN
- China
- Prior art keywords
- compound
- ethyl
- pharmaceutically acceptable
- pyrrolidin
- naphthyridin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 OC(CC(*N1C=C[C@@](CCc2nc(NCCC3)c3cc2)C1)c1cc(C2=CC=N*2)cc(N2CCOCC2)c1)=O Chemical compound OC(CC(*N1C=C[C@@](CCc2nc(NCCC3)c3cc2)C1)c1cc(C2=CC=N*2)cc(N2CCOCC2)c1)=O 0.000 description 3
- PADPDQMNQLHYJS-SALQQRKASA-N C/C(/OC(/C=C/COC(C)=O)=O)=C\CN Chemical compound C/C(/OC(/C=C/COC(C)=O)=O)=C\CN PADPDQMNQLHYJS-SALQQRKASA-N 0.000 description 1
- IVHZGZPSPWEELH-UHFFFAOYSA-N CC(C)(C)CC1=C(C)OC2OC2O1 Chemical compound CC(C)(C)CC1=C(C)OC2OC2O1 IVHZGZPSPWEELH-UHFFFAOYSA-N 0.000 description 1
- HFNDFVVHUFIPDE-QDPGVEIFSA-N COC(C[C@H](CN1C[C@H](CCc2ccc(CCCN3)c3n2)CC1)c1cc(N2CCOCC2)cc(C2CC2)c1)=O Chemical compound COC(C[C@H](CN1C[C@H](CCc2ccc(CCCN3)c3n2)CC1)c1cc(N2CCOCC2)cc(C2CC2)c1)=O HFNDFVVHUFIPDE-QDPGVEIFSA-N 0.000 description 1
- DSIZWMBDZKYEIX-GEPVFLLWSA-N OC(CC(CN1C[C@H](CCc2nc(NCCC3)c3cc2)CC1)c1cc(-[n]2nccc2)cc(N2CCOCC2)c1)=O Chemical compound OC(CC(CN1C[C@H](CCc2nc(NCCC3)c3cc2)CC1)c1cc(-[n]2nccc2)cc(N2CCOCC2)c1)=O DSIZWMBDZKYEIX-GEPVFLLWSA-N 0.000 description 1
- YCKIGNXHCIMFCX-KKGVWULHSA-N OC(C[C@H](CCCC1C[C@H](CCc2nc(NCCC3)c3cc2)CCC1)c1cc(-c2ccn[nH]2)cc(N2CCOCC2)c1)=O Chemical compound OC(C[C@H](CCCC1C[C@H](CCc2nc(NCCC3)c3cc2)CCC1)c1cc(-c2ccn[nH]2)cc(N2CCOCC2)c1)=O YCKIGNXHCIMFCX-KKGVWULHSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1417018.7 | 2014-09-26 | ||
| GBGB1417018.7A GB201417018D0 (en) | 2014-09-26 | 2014-09-26 | Novel compounds |
| PCT/EP2015/071798 WO2016046241A1 (en) | 2014-09-26 | 2015-09-22 | Novel compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107074850A true CN107074850A (zh) | 2017-08-18 |
Family
ID=51901174
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201580052202.3A Pending CN107074850A (zh) | 2014-09-26 | 2015-09-22 | 新化合物 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US10004724B2 (https=) |
| EP (1) | EP3197895B1 (https=) |
| JP (1) | JP6672276B2 (https=) |
| KR (1) | KR20170054413A (https=) |
| CN (1) | CN107074850A (https=) |
| AU (1) | AU2015320874A1 (https=) |
| BR (1) | BR112017006240A2 (https=) |
| CA (1) | CA2962319A1 (https=) |
| ES (1) | ES2796235T3 (https=) |
| GB (1) | GB201417018D0 (https=) |
| RU (1) | RU2017114352A (https=) |
| WO (1) | WO2016046241A1 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201305668D0 (en) | 2013-03-28 | 2013-05-15 | Glaxosmithkline Ip Dev Ltd | Avs6 Integrin Antagonists |
| GB201417011D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| GB201417094D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| GB201417002D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compound |
| GB201604680D0 (en) | 2016-03-21 | 2016-05-04 | Glaxosmithkline Ip Dev Ltd | Chemical Compounds |
| AU2017359023B2 (en) | 2016-11-08 | 2021-12-09 | Bristol-Myers Squibb Company | 3-substituted propionic acids as alpha v integrin inhibitors |
| WO2018089357A1 (en) | 2016-11-08 | 2018-05-17 | Bristol-Myers Squibb Company | INDAZOLE DERIVATIVES AS αV INTEGRIN ANTAGONISTS |
| ES2984394T3 (es) | 2016-11-08 | 2024-10-29 | Bristol Myers Squibb Co | Compuestos mono y espirocíclicos que contienen ciclobutano y azetidina como inhibidores de la integrina alfa v |
| BR112019009245A2 (pt) | 2016-11-08 | 2019-07-16 | Bristol-Myers Squibb Company | azol amidas e aminas como inibidores de alfav integrina |
| HRP20210228T1 (hr) | 2016-11-08 | 2021-03-19 | Bristol-Myers Squibb Company | Amidi pirola kao inhibitori alfa v integrina |
| US10696672B2 (en) | 2016-12-23 | 2020-06-30 | Pliant Therapeutics, Inc. | Amino acid compounds and methods of use |
| MA52117A (fr) | 2017-02-28 | 2022-04-06 | Morphic Therapeutic Inc | Inhibiteurs de l'intégrine (alpha-v) (bêta-6) |
| MX394210B (es) | 2017-02-28 | 2025-03-04 | Morphic Therapeutic Inc | INHIBIDORES DE INTEGRINA AVß6. |
| KR102700471B1 (ko) | 2017-11-07 | 2024-08-28 | 브리스톨-마이어스 스큅 컴퍼니 | 알파 v 인테그린 억제제로서의 피롤로피라진 유도체 |
| WO2020047208A1 (en) | 2018-08-29 | 2020-03-05 | Morphic Therapeutic, Inc. | Inhibitors of (alpha-v)(beta-6) integrin |
| WO2020047239A1 (en) | 2018-08-29 | 2020-03-05 | Morphic Therapeutic, Inc. | INHIBITING αV β6 INTEGRIN |
| SI3844162T1 (sl) | 2018-08-29 | 2025-06-30 | Morphic Therapeutic, Inc. | Zaviralci integrina alfa v beta6 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001024797A1 (en) * | 1999-10-04 | 2001-04-12 | Merck & Co., Inc. | Integrin receptor antagonists |
| WO2005082889A1 (en) * | 2004-02-18 | 2005-09-09 | Janssen Pharmaceutica N.V. | Piperidinyl targeting compounds that selectively bind integrins |
| WO2014154725A1 (en) * | 2013-03-28 | 2014-10-02 | Glaxosmithkline Intellectual Property Development Limited | Naphthyridine derivatives useful as alpha-v-beta-6 integrin antagonists |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2315370A1 (en) | 1997-12-17 | 1999-06-24 | Merck & Co., Inc. | Integrin receptor antagonists |
| KR20010033248A (ko) | 1997-12-17 | 2001-04-25 | 폴락 돈나 엘. | 인테그린 수용체 길항제 |
| CN1589145A (zh) | 1999-06-02 | 2005-03-02 | 麦克公司 | αv整联蛋白受体拮抗剂 |
| WO2000078317A1 (en) | 1999-06-23 | 2000-12-28 | Merck & Co., Inc. | Integrin receptor antagonists |
| PL355011A1 (en) | 1999-11-08 | 2004-03-22 | Merck & Co, Inc. | Process and intermediates for the preparation of imidazolidinone alpha v integrin antagonists |
| US7119098B2 (en) * | 2000-06-15 | 2006-10-10 | Pharmacia Corporation | Heteroarylakanoic acids as intergrin receptor antagonists |
| AU7793501A (en) | 2000-07-26 | 2002-02-05 | Merck & Co Inc | Alpha v integrin receptor antagonists |
| WO2002022616A2 (en) | 2000-09-14 | 2002-03-21 | Merck & Co., Inc. | Alpha v integrin receptor antagonists |
| CA2432504A1 (en) | 2001-01-03 | 2002-07-11 | Merck & Co., Inc. | Methods and compositions for treating periodontal disease |
| DE10112771A1 (de) | 2001-03-16 | 2002-09-26 | Merck Patent Gmbh | Inhibitoren des Integrins alpha¶v¶beta¶6¶ |
| EP1592421A1 (en) | 2002-12-20 | 2005-11-09 | Pharmacia Corporation | Heteroarylalkanoic acids as integrin receptor antagonists |
| EP2139882B1 (en) | 2007-03-23 | 2013-12-25 | Amgen Inc. | 3- substituted quinoline or quinoxaline derivatives and their use as phosphatidylinositol 3-kinase (pi3k) inhibitors |
| EP2211615A4 (en) | 2007-10-22 | 2010-10-13 | Glaxosmithkline Llc | PYRIDOSULFONAMIDE DERIVATIVES AS PI3 KINASE INHIBITORS |
| WO2011111880A1 (ko) | 2010-03-08 | 2011-09-15 | 주식회사 메디젠텍 | 세포핵에서 세포질로의 ｇｓｋ３의 이동을 억제하는 화합물을 함유하는 세포핵에서 세포질로의 gsk3 이동에 의해 발생되는 질환의 치료 또는 예방용 약학적 조성물 |
| WO2015048819A1 (en) | 2013-09-30 | 2015-04-02 | The Regents Of The University Of California | Anti-alphavbeta1 integrin compounds and methods |
| GB201417011D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| GB201417002D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compound |
| GB201417094D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| US9790222B2 (en) | 2015-02-19 | 2017-10-17 | Scifluor Life Sciences, Inc. | Fluorinated tetrahydronaphthyridinyl nonanoic acid derivatives and uses thereof |
| WO2016145258A1 (en) | 2015-03-10 | 2016-09-15 | The Regents Of The University Of California | Anti-alphavbeta1 integrin inhibitors and methods of use |
| GB201604589D0 (en) | 2016-03-18 | 2016-05-04 | Glaxosmithkline Ip Dev Ltd | Chemical compound |
| GB201604680D0 (en) | 2016-03-21 | 2016-05-04 | Glaxosmithkline Ip Dev Ltd | Chemical Compounds |
| GB201604681D0 (en) | 2016-03-21 | 2016-05-04 | Glaxosmithkline Ip Dev Ltd | Chemical Compounds |
-
2014
- 2014-09-26 GB GBGB1417018.7A patent/GB201417018D0/en not_active Ceased
-
2015
- 2015-09-22 ES ES15767479T patent/ES2796235T3/es active Active
- 2015-09-22 RU RU2017114352A patent/RU2017114352A/ru unknown
- 2015-09-22 CN CN201580052202.3A patent/CN107074850A/zh active Pending
- 2015-09-22 AU AU2015320874A patent/AU2015320874A1/en not_active Abandoned
- 2015-09-22 JP JP2017516386A patent/JP6672276B2/ja not_active Expired - Fee Related
- 2015-09-22 WO PCT/EP2015/071798 patent/WO2016046241A1/en not_active Ceased
- 2015-09-22 KR KR1020177007735A patent/KR20170054413A/ko not_active Withdrawn
- 2015-09-22 CA CA2962319A patent/CA2962319A1/en active Pending
- 2015-09-22 BR BR112017006240A patent/BR112017006240A2/pt not_active Application Discontinuation
- 2015-09-22 US US15/514,414 patent/US10004724B2/en not_active Expired - Fee Related
- 2015-09-22 EP EP15767479.7A patent/EP3197895B1/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001024797A1 (en) * | 1999-10-04 | 2001-04-12 | Merck & Co., Inc. | Integrin receptor antagonists |
| WO2005082889A1 (en) * | 2004-02-18 | 2005-09-09 | Janssen Pharmaceutica N.V. | Piperidinyl targeting compounds that selectively bind integrins |
| WO2014154725A1 (en) * | 2013-03-28 | 2014-10-02 | Glaxosmithkline Intellectual Property Development Limited | Naphthyridine derivatives useful as alpha-v-beta-6 integrin antagonists |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2017528506A (ja) | 2017-09-28 |
| RU2017114352A (ru) | 2018-10-26 |
| GB201417018D0 (en) | 2014-11-12 |
| EP3197895B1 (en) | 2020-03-11 |
| KR20170054413A (ko) | 2017-05-17 |
| US20170290818A1 (en) | 2017-10-12 |
| EP3197895A1 (en) | 2017-08-02 |
| JP6672276B2 (ja) | 2020-03-25 |
| ES2796235T3 (es) | 2020-11-26 |
| CA2962319A1 (en) | 2016-03-31 |
| AU2015320874A1 (en) | 2017-03-09 |
| US10004724B2 (en) | 2018-06-26 |
| WO2016046241A1 (en) | 2016-03-31 |
| BR112017006240A2 (pt) | 2017-12-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107074850A (zh) | 新化合物 | |
| CN107074851B (zh) | 作为αvβ6整联蛋白拮抗剂用于治疗例如纤维变性疾病的萘啶衍生物 | |
| US10450312B2 (en) | Naphthyridine derivatives useful as alpha-V-beta-6 integrin antagonists | |
| US10487080B2 (en) | Naphthyridines as integrin antagonists | |
| CN108779114A (zh) | 作为整联蛋白拮抗剂的萘啶化合物 | |
| CN108699036A (zh) | 化合物(s)-4-((s)-3-氟-3-(2-(5,6,7,8-四氢-1,8-萘啶-2-基)乙基)吡咯烷-1-基)-3-(3-(2-甲氧基乙氧基)苯基)丁酸(1:1)柠檬酸盐 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20170818 |